Lisa Enterprises

Glimda (Glimepiride + Metformin + Voglibose) Tablets

Glimda is a triple-combination oral diabetes medication designed to support comprehensive blood glucose control in adults with type 2 diabetes. It combines three clinically proven agents—Glimepiride, Metformin Hydrochloride, and Voglibose—each working through different mechanisms to help regulate blood sugar more effectively than single-agent therapy alone. This combination supports improved glycemic balance throughout the day and after meals when used alongside diet and lifestyle changes under medical guidance.

• Glimepiride stimulates the pancreas to release more insulin, helping lower high blood glucose.

• Metformin Hydrochloride reduces glucose production in the liver and improves insulin sensitivity, aiding steady glucose utilization.

• Voglibose slows carbohydrate breakdown and absorption in the gut, helping reduce post-meal glucose spikes.

Together, these actions work in harmony to help patients achieve better overall metabolic control.

• Supports comprehensive blood glucose control, including after meals and between doses.

• Helps reduce both fasting and post-meal blood sugar levels, improving overall metabolic balance.

• Promotes steadier glycemic stability, which may reduce the risk of long-term diabetes complications.

• Triple-action formulation combining Glimepiride, Metformin, and Voglibose for multi-mechanism glucose control.

• Convenient once-daily tablet (or as directed), simplifying therapy for eligible patients.

• Clinically trusted components, commonly used in diabetes management protocols.

Short Description:
Glimda tablets combine Glimepiride, Metformin Hydrochloride, and Voglibose to provide comprehensive support for blood sugar management in type 2 diabetes, helping improve fasting and post-meal glucose levels through a multi-mechanism formulation.